Dogs as young as 8 weeks old can be protected from fleas and ticks through the use of Bravecto 1-Month, a chewable medication newly approved by the U.S. Food and Drug Administration.
The manufacturer, Merck Animal Health, did not announce a launch date for the product, which like other Bravecto preventives contains the active ingredient fluralaner, an ectoparasiticide belonging to the isoxazoline class. Bravecto 1-Month delivers four weeks of protection compared with longer periods for original Bravecto chews and Bravecto Topical Solution, both of which are approved for dogs at least 6 months old. The topical product and Bravecto Plus, another spot-on preventive, are formulated for cats.
“With Bravecto 1-Month, we have expanded our portfolio with a superior advance in the fight against parasites, as well as provided both adult dogs and puppies with flea and tick protection that delivers immediate and persistent killing activity,” said K.J. Varma, BVSc, Ph.D., senior vice president of research and development at Merck Animal Health.
The new parasiticide, approved for dogs weighing at least 4.4 pounds, kills adult fleas, prevents flea infestations and fights four tick species: black-legged, American dog, brown dog and lone star.
Bravecto 1-Month will be available in weight-dependent dosages of 45, 100, 200, 400 and 560 milligrams.
Did you know a subscription to Today’s Veterinary Business is free to qualified veterinary professionals? All you have to do is sign up here (and renew each year). You also can sign up to receive the Today’s Veterinary Business weekly e-newsletter.